AstraZeneca AB & Anr. v. Intas Pharmaceuticals Ltd. & Others
Whether a patentee holding both an earlier genus patent and a later species patent over the same molecule could obtain an interim injunction against generic makers.
What the court held
The Division Bench refused interim relief and dismissed the appeals. It reasoned that a patentee cannot treat a molecule as covered and disclosed by an earlier broad claim for one purpose while presenting the later patent as a separate invention for another. If the compound already fell within the earlier genus, the later claim raised a serious question about whether a further inventive step existed. With validity credibly in doubt and cheaper alternatives already on the market, the balance was against restraining the generic makers.
Why it matters to a reader of this provision
Genus and species patenting is common in pharmaceuticals, and this judgment shows how Indian courts handle the coverage and disclosure argument when both patents are asserted. It is a practical illustration of a credible validity challenge defeating an interim injunction, and of the weight courts give to price and to the availability of alternatives when deciding whether to restrain a generic entrant.
Provisions this judgment interprets
Open a provision for the plain-language explanation, the worked example and the forms and deadlines it touches.
Does this judgment affect your matter?
Whether a decision helps or hurts depends entirely on your facts and your claims. A patent professional can tell you which.